About 30 results found for searched term "WS6" (0.093 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M8952 | WS6 | IκB/IKK |
| WS6 is a novel beta cell proliferation simulator, which promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability). | ||
| M1760 | Palomid 529 | mTOR |
| P529 | ||
| Palomid 529 (P529) is a novel potent PI3K/Akt/mTOR inhibitor and shows a potent antiproliferative activity in the NCI-60 cell lines panel, with growth inhibitory 50 (GI50) <35 μM. | ||
| M2792 | Ki16198 | LPL Receptor |
| Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6. | ||
| M2982 | Ro 31-8220 Mesylate | PKC |
| Bisindolylmaleimide IX Mesylate | ||
| Ro 31-8220 is a pan-PKC inhibitor with IC50 of 5 nM, 24 nM, 14 nM, 27 nM, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively, and also shows potent inhibition against MAPKAP-K1b, MSK1, GSK3β and S6K1. | ||
| M3134 | Z-DEVD-FMK | Caspase |
| Caspase-3 Inhibitor | ||
| Z-DEVD-FMK is a specific, irreversible Caspase-3 inhibitor with an IC50 of 18 μM, and also shows potent inhibition on caspase-6, caspase-7, caspase-8, and caspase-10. | ||
| M3524 | BRL-15572 dihydrochloride | 5-HT Receptor |
| BRL-15572 2HCl | ||
| BRL-15572 is a 5-HT1D receptor antagonist with pKi of 7.9, also shows a considerable affinity at 5-HT1A and 5-HT2B receptors, exhibiting 60-fold selectivity over 5-HT1B receptor. | ||
| M4903 | Ciprofloxacin | Topoisomerase |
| Bay 09867 | ||
| Ciprofloxacin is a fluoroquinolone antibiotic, shows broad and potent antibacterial activity, with MIC90 of 0.024-6 μM. | ||
| M6161 | GSK369796 Dihydrochloride | Potassium Channel |
| GSK369796 shows antimalerial activity with IC50 values of 11.2 nM for 3D7 strain, 12.6 nM for HB3 strain, 17.6 nM for K1 strain. | ||
| M6255 | JPH203 | Autophagy |
| KYT-0353 | ||
| JPH203, a selective L-type amino acid transporter 1 (LAT1) inhibitor, shows a dramatic inhibition of leucine uptake (IC50=0.06 µM) and cell growth (IC50=4.1 µM) in human colon cancer cells (HT-29), human oral cancer cells (YD-38) and leukemic cells. | ||
| M7065 | NU9056 | Histone Acetyltransferase |
| NU 9056 | ||
| NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an IC50 of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells. | ||
| M10370 | Larazotide acetate | Others |
| AT-1001 | ||
| Larazotide acetate also known as AT-1001, is a tight junction regulator and reverses leaky junctions to their normally closed state. Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. | ||
| M10966 | SY-5609 | CDK |
| CDK7-IN-3 | ||
| SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent CDK7 inhibitor with a KD of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), CDK12 (Ki=870 nM). | ||
| M13521 | Sesamol | Apoptosis |
| Sesamol is a constituent of sesame oil. Sesamol shows a free radical scavenging activity. Sesamol shows an IC50=5.95±0.56 μg/mL in the DPPH assay. Anti-oxidant activities. Anticancer activities. | ||
| M13624 | 6RK73 | Deubiquitinase |
| 6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC50 of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC50=236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer. | ||
| M13655 | TK216 | DNA/RNA Synthesis |
| TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. TK216 directly binds EWS-FLI1 and inhibits EWS-FLI1 protein interactions. TK216 blocks the binding between EWS-FLI1 and RNA helicase A. TK216 has anticancer activity. | ||
| M13671 | ACY-957 | HDAC |
| ACY-957 is an orally active and selective inhibitor of HDAC1 and HDAC2, with IC50s of 7 nM, 18 nM, and 1300 nM against HDAC1/2/3, respectively, and shows no inhibition on HDAC4/5/6/7/8/9. | ||
| M13770 | BCECF | Fluorescent Dye |
| 2′,7′-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein | ||
| BCECF is a pH-sensitive fluorescent dye. BCECF allows measurements in the physiological pH range 6.0–8.0. Excitation ratio: 490/440 nm; Emission intensity: 535 nm. | ||
| M13832 | GSK467 | Histone demethylase |
| GSK467 is a cell penetrant and selective KDM5B (JARID1B or PLU1) inhibitor with a Ki of 10 nM, shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members. | ||
| M13844 | CARM1-IN-1 | PRMTs |
| CARM1-IN-1 is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM). | ||
| M13845 | CARM1-IN-1 hydrochloride | PRMTs |
| CARM1-IN-1 hydrochloride is a potent and specific CARM1(Coactivator-associated arginine methyltransferase 1) inhibitor with IC50 of 8.6 uM; shows very low activity against PRMT1 and SET7(IC50 > 600 uM). | ||
| M14284 | Pico145 | TRP Channel |
| HC-608; Zerencotrep | ||
| Pico145 (HC-608; Zerencotrep) is a remarkable inhibitor of TRPC1/4/5 channels, inhibits (−)-englerin A-activated TRPC4/TRPC5 channels, with IC50s of 0.349 and 1.3 nM in cells, and shows no effect on TRPC3, TRPC6, TRPV1, TRPV4, TRPA1, TRPM2, TRPM8. | ||
| M14500 | Osoresnontrine | PDE |
| BI-409306 | ||
| Osoresnontrine (BI-409306) is a potent and selective PDE9A inhibitor, with an IC50 of 52 nM, and shows weak activity against other PDEs, such as PDE1A (IC50, 1.4 µM), PDE1C (IC50, 1.0 µM), PDE2A, PDE3A, PDE4B, PDE5A, PDE6AB, PDE7A, and PDE10A (IC50 all > 10 μM); Osoresnontrine can be used in the research of memory enhancement in CNS disorders. | ||
| M18713 | Chelidonic acid | NF-κB |
| Chelidonic acid is an antimicrobial. Chelidonic acid also shows anti-inflammatory activity. Chelidonic acid has potential to inhibit IL-6 production by blocking NF-κB and caspase-1. Chelidonic acid is a glutamate decarboxylase inhibitor, with a Ki of 1.2 μM. | ||
| M19179 | Prudomestin | Xanthine Oxidase |
| Prudomestin, isolated from the heartwood of Prunus domestica, shows potent xanthine oxidase (XO) inhibitory activity (IC50≈6 µM). | ||
| M19198 | Gypsogenin | Others |
| Gypsogenin shows antiangiogenic activity and the significant cytotoxicity against H460. | ||
| M20644 | TH34 | HDAC |
| TH34 is a HDAC inhibitor that shows pronounced selectivity for HDACs 6, 8 and 10 over HDACs 1, 2 and 3. In a NanoBRET assay, TH34 strongly binds HDAC6, 8 and 10 with low-micromolar IC50 concentrations (HDAC6: 4.6 µM, HDAC8: 1.9 µM, HDAC10: 7.7 µM). | ||
| M21150 | TMX-4116 | Casein Kinase |
| TMX-4116 is a casein kinase 1α (CK1α) degradation agent. tmx-4116 shows a preference for CK1α degradation in MOLT4, Jurkat and MM.1S cells with DC50 less than 200 nM. tmx-4116 can be used in the study of multiple myeloma. | ||
| M22505 | Recombinant Enhanced Green Fluorecence Protein (E. coli) | Cytokines and Growth Factors |
| reGFP; EGFP | ||
| Recombinant Enhanced Green fluorescent protein (EGFP) is a 26.9 kDa protein (composed of 239 a.a. residues) that shows green fluorescence in short-wave light (blue to ultraviolet). Enhanced GFP (eGFP) has S65T and F64L mutations, which make GFP show increased fluorescence and fold more efficiently under 37℃, respectively. | ||
| M24776 | IMAB027 | Others |
| ASP1650 | ||
| IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6+ ovarian and testicular cancer cell lines. | ||
| M25286 | Canakinumab | IL Receptor/Related |
| Ilaris ACZ 885 | ||
| Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
